With one of the most diverse lung cancer development programs, Novartis is focused on investments to advance the science, drive treatment and make an impact on patients
The company plans to file its NDA in China and MAA in the EU in 2022, making Hansizhuang potentially to be the world's first PD-1 inhibitor for the first-line treatment of SCLC
This state-of-art technology will help pulmonologists to diagnose lung cancer in the very early stages helping the patient get an early surgical resection
Clinical trials for minimally invasive therapy procedures using advanced imaging from Philips Lung Suite start with successful first cases
Arctoris and Evariste Technologies announce a joint venture to develop novel small molecule kinase inhibitors for non-small cell lung cancer (NSCLC)
Collaboration aims to capture patient-to-patient variability to determine the best treatment for every cancer
Tepmetko is the first and only oral MET inhibitor to be approved in the European Economic Area for treating adult patients with advanced NSCLC harboring alterations leading to METex14 skipping, who require systemic therapy following prior treatment
First Positive Study for KEYTRUDA in Adjuvant Stage IB-IIIA NSCLC
After double lung transplantation, he was discharged without supplemental oxygen on the eleventh day
Cryo-technology helps in early diagnosis and palliative care in later stages of cancer
Subscribe To Our Newsletter & Stay Updated
